ERS Genomics
ERS Genomics was formed to commercialize the foundational CRISPR-Cas9 intellectual property held by co-inventor, co-owner and Nobel Prize-winner Dr. Emmanuelle Charpentier. The team has decades of experience in the field of genome editing and its application, in business development and licensing, licensing preclinical and clinical stage therapeutic products and drug delivery technologies, genome editing technologies as well as overseeing research and development.
Latest ERS Genomics Content
Product News
ERS Genomics and IRBM Sign CRISPR/Cas9 License Agreement
License agreement provides IRBM access to CRISPR gene editing technology to be applied across its drug discovery services offering.
Product News
Ers Genomics and StemSight Sign CRISPR/Cas9 License Agreement
License agreement provides StemSight access to CRISPR/Cas9 technology to be applied in development of cell therapies for corneal blindness.
Product News
Key Charpentier/Doudna CRISPR Patent Upheld by Japanese Patent Office
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, announced its second Japanese Patent.
Industry Insight
How CRISPR Is Transforming High-Throughput Screening
This article walks through the fundamentals of CRISPR screening and its most exciting applications, including unpicking cellular signaling networks, discovering how viruses like COVID-19 infect our cells and finding new drug targets.
Product News
ERS Genomics and Lepton Pharmaceuticals LTD Enter CRISPR/Cas9 License Agreement
ERS Genomics Limited is pleased to announce a new license agreement with Lepton Pharmaceuticals LTD.
Industry Insight
What’s Hot in Synthetic Biology Right Now?
In this opinion piece, Eric Rhodes, CEO of ERS Genomics, shares his roundup of some of the most exciting innovations in synthetic biology right now.
Product News
New CRISPR/Cas9 License Agreement for ERS Genomics and Cytosurge
ERS Genomics Limited has announced a new license agreement with Cytosurge AG. This is a non-exclusive licensing agreement granting Cytosurge access to the ERS CRISPR/Cas9 patent portfolio.
Article
Cas9 or Cas12? Picking the Right CRISPR System for Your Research
What are the major differences between Cas9 and Cas12, and how can you decide which is right for your research?
Advertisement
